Halda Therapeutics

Taking Hold, Conquering Cancer. Discovering novel medicines to target cancer and overcome drug resistance. Official Twitter for Halda Therapeutics.

[Halda Therapeutics @HaldaTx]

We welcome 2024 at Halda! We're doubling down against cancer and in our commitment to creating a new class of precision RIPTAC™ therapeutics.
https://t.co/t1j5vRPrpv

[Halda Therapeutics @HaldaTx]

We are delighted to welcome Stephanie Scarcella, our new Office Manager, to the Halda team. #welcometotheteam #newhavenct

[Halda Therapeutics @HaldaTx]

Honored that Halda Therapeutics was selected as a Top 10 Start-up to Watch by @cenmag, recognizing our progress with RIPTAC™ therapeutics, a new class of precision #cancer medicines.
#HoldandKillCancer #RIPTACtherapeutics
https://t.co/wY9u8qlRNy

[Halda Therapeutics @HaldaTx]

We are thrilled to welcome Jessica Tonini, our new Controller, to the Halda team. #welcometotheteam #newhavenct #chemistry

[Halda Therapeutics @HaldaTx]

It’s a Halda Halloween! We are a collective force for fun and camaraderie when we get together for fun, as well as in our work developing cancer drugs.

[Halda Therapeutics @HaldaTx]

Tomorrow CSO Kat Kayser-Bricker presents at the 30th Annual Prostate Cancer Foundation Scientific Retreat in CA, sharing Halda’s prostate cancer RIPTAC™ therapeutic with novel hold-and-kill mechanism designed to overcome drug resistance common in #prostatecancer. #PCFretreat23

[Halda Therapeutics @HaldaTx]

We're proud that our CSO Kat Kayser-Bricker was chosen as a Women of Innovation 2023 finalist in the Research Innovation & Leadership category by the CT Technology Council's Women of Innovation. She will be honored as a #WomenInSTEM leader at an event this evening. #WOI23

[Halda Therapeutics @HaldaTx]

At #AACR2023, our preclinical data for prostate cancer RIPTACs show anti-tumor activity superior to standard of care and the promise of a novel approach to overcome bypass mechanisms of resistance that limit today's precision medicines. #HoldandKillCancer
https://t.co/5FxvglmxuX

[Halda Therapeutics @HaldaTx]

Halda news at #AACR23: Halda presents preclinical data for RIPTAC™ therapeutics demonstrating oral efficacy as a monotherapy for the treatment of prostate cancer
https://t.co/qG9I7SCLXU

[Katherine A Donovan @kdonovan1008]

Another amazing double seminar coming up this week💥

[Halda Therapeutics @HaldaTx]

At ASCO #GU23, Halda’s prostate cancer RIPTAC™ therapeutic shows a novel cancer cell-killing mechanism designed to leverage Androgen Receptor for tumor targeting, independent of its cancer-driver status, and overcome common cancer drug resistance.
https://t.co/fYPtwV9xwh

[Halda Therapeutics @HaldaTx]

At ASCO #GU23, we’re sharing preclinical data for our prostate cancer RIPTAC™ therapeutic with a novel ‘hold and kill’ mechanism, demonstrating superior in vivo anti-tumor activity to standard of care.
#HoldandKillCancer
https://t.co/EGdPLx5umZ

[Halda Therapeutics @HaldaTx]

This C&E News article digs into our story and what sets apart Halda’s novel cancer drug modality, #RIPTACtherapeutics
https://t.co/fxZPyMJa9Y

[BioPharma Dive @BioPharmaDive]

With latest startup, repeat #biotech founder Craig Crews tries to ‘hold and kill’ tumors https://t.co/xWkf3EG8bt by @BentheFidler

[Halda Therapeutics @HaldaTx]

We’re thrilled to unveil Halda’s RIPTAC™ therapeutics to the cancer drug discovery community. @ky_lahucik @endpointsnews explores our revolutionary approach to eradicate cancer cells in a new way.
#HoldandKillCancer
https://t.co/SrMvj0DziJ

[Halda Therapeutics @HaldaTx]

RIPTAC™ therapeutics do not rely on oncogenic driver proteins, opening a new realm of cancer targeting. Scientific founder Craig Crews of Yale and CSO Kat Kayser-Bricker share the origin story for this new cancer-fighting drug modality in this blogpost.
https://t.co/VURqiVX2mw

[Halda Therapeutics @HaldaTx]

Halda’s novel RIPTAC™ modality is an evolution of the work of its scientific founder, Prof. Craig Crews, and his Yale lab’s multi-decade pioneering of heterobifunctional small molecule medicines.
#HoldandKillCancer
https://t.co/t1j5vRPrpv

[Halda Therapeutics @HaldaTx]

Halda unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO #GU23 Symposium. Preclinical data for a prostate cancer RIPTAC therapeutic demonstrates superior in vivo efficacy to standard of care.
#RIPTACtherapeutics
https://t.co/fYPtwV9xwh

[Halda Therapeutics @HaldaTx]

Halda Therapeutics steps into the spotlight with RIPTAC™ therapeutics, a new class of precision medicines to defeat cancer.
#HoldandKillCancer #RIPTACtherapeutics
https://t.co/LehsZBA4xM